Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies (NCT05226871)
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIES
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: * Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study * Must agree to follow the reproductive criteria * Are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * Can give signed informed consent documents Participants in this study will continue to receive treatment as they were in the parent study. The time by which participants will take part in this study is retrospective (after completed parent study). We will examine the experiences of people receiving the study medicine(s). This will help us determine if the study medicine(s) are safe. During this time, the participants will be monitored for the safety of the study medicine(s).
Who can join: Review the eligibility criteria below.
Location: UCSF Medical Center at Mission Bay — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- UCSF Medical Center at Mission Bay — San Francisco, California
- The First Affiliated Hospital of Anhui Medical University — Hefei, Anhui
- Beijing Cancer Hospital — Beijing, Beijing Municipality
- Sun Yat-sen Memorial Hospital of Sun Yat-sen University — Guangzhou, Guangdong
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
- Henan Cancer Hospital — Zhengzhou, Henan
- Hubei Cancer Hospital — Wuhan, Hubei
- The First Hospital of Jilin University — Changchun, Jilin
- Liaoning Cancer Hospital and Institute — Shenyang, Liaoning
- The First Hospital of China Medical University — Shenyang, Liaoning
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality
- Cancer Hospital Chinese Academy of Medical Science — Beijing,
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez" — Monterrey, Nuevo León
- National Cancer Center — Goyang-si, Gyeonggi-do
- Samsung Medical Center — Seoul, Seoul-teukbyeolsi [seoul]
- Seoul National University Hospital — Seoul,
- National Cheng Kung University Hospital — Tainan,
- Mackay Memorial Hospital — Taipei,
- Faculty of Medicine, Ramathibodi Hospital, Mahidol University — Ratchathewi, Bangkok
- Department of Medicine, Faculty of Medicine Siriraj Hospital — Bangkok,
- Regional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center" — Chernivtsi, Chernivetska Oblast
- Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council — Dnipro,
- Municipal non-profit enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council — Ivano-Frankivsk,
📞 Contact the Study Coordinator
Phone: (877) 827-3222
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.